Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
  • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Definitions

• the present invention provides new tertiary 8-hydroxyquinoline-7- carboxamide derivatives and pharmaceutically acceptable salts thereof, which are useful as antifungal agents and a process for their preparation. Specifically, these compounds were tested against Tricophyton Rubrum, Tricophyton entagrophytes, Aspergillus Niger and Scopulariopsis Brevicaulis. Many of these compounds are also active against Candida species such as Candida Albicans and Candida Glabrata.
• Pathogenic fungi can be divided in two categories: fungi that are able to induce diseases in normal subjects and less invasive fungi that are able to produce diseases only in critically ill hosts.
• ICU intensive care units
• the UK hospitalized incidence of candidemia is about 3 per 100,000 bed days, and 40% to 52% of ail cases occur in ICU (Schelenz S., J. Antimicrob. Chemother. 2008; 61, Suppl 1, 31-34). This kind of mycoses is frequently associated with considerable morbidity and mortality.
• the attributable mortality rate is about 38%, although it can vary between 5% and 71 %.
• the disease incidence ranges from 0.3% to 5.8% with an overall mortality rate exceeding 80% (Trof R. J.
• Candida and Aspergillus species are the most common pathogens responsible for nosocomial superficial and invasive mycoses in hematologic malignancies and bone marrow transplanted patients. In these patients the mortality associated with the systemic candidosis is very high (50-90%).
• infective complications are more frequent in lung-transplanted patients.
• the increased susceptibility is mainly due to the constant exposure to the external environment.
• Parallel to immunosuppressive treatment intensity invasive fungal infection may occur during the first days after surgical operation, its frequency is highest in the first two months and decreases after 6 months but it can occur also years after transplantation (Hamacher J. et al, Eur, Respir. J., 1999; 13, 180-186).
• Invasive fungal infections are also frequent in other kind of solid organ transplantation such as kidney and liver transplants for which incidence of 5 to 50% are reported (Dictar M. O. et al, Med Mycoi. , 2000; 38 Suppl. 1 , 251- 258).
• Mycoses are one of the major causes of morbidity in patients with AIDS and the incidence and seventy of these infections increase with disease progression and the consequent impairment of T-cell-mediated immunity.
• the incidence of the different mycoses is closely related to the endemic opportunistic fungi present in the area of residence.
• mycoses that affect AIDS patients are histopiasmosis, blastomycosis, coccidioidomycosis and paracoccidiomycosis (Sarosi G. A., Davies S. F., West J. Med., 1996; 164, 335-340).
• Mucosal Candida infections are also extremely common. In normal patients all these mycosis are usually self-!imited but in immunodepressed patients become highly invasive resulting in progressive and widespread dissemination.
• Azoles introduced in the second half of the 1970s, are blockers of ergosterol synthesis.
• the use of the drugs belonging to this family is limited by their narrow spectrum of activity.
• Voriconazole for example, is more active than Amphotericin B for the treatment of invasive aspergillosis but has no activity against zygomycetes (Johnson L. B., Kauffman C. A., Clin. Infect. D/s., 2003, 36, 630-637).
• the azoles employment is also limited by the induction of several side effects.
• Azoles interact with mammalian p450 enzymes resulting in interference with the metabolism of other drugs and, in addition, some azoles such as ketoconazole are able to block the cardiac potassium channel Kv1 .5 causing Q-T prolongation and 'torsade de pointes' (Dumaine R., Roy M. L, Brown A. M., J. Pharmacol. Exp. Ther., 1998; 286, 727-735).
• Allylamines such as Terbinafine bind to and inhibit squalene epoxidase resulting in a block of ergosterol synthesis. These drugs are very potent against Dermatophytes while their activity against Candida species is very poor. In some cases treatment with allylamines is followed by severe cutaneous adverse reactions.
• An recent multinational case-control study (euroSCAR) (Sidoroff A. et al, Br. J. Dermatol., 2007; 15, 989-996) revealed that Terbinafine systemic treatment is strongly associated with the development of an acute generalized exanthematous pustolosis (AGEP).
• AGEP acute generalized exanthematous pustolosis
• This disease is characterized by the rapid occurrence of many sterile, nonfoliicular pustules, usually accompanied by leucocytosis and fever.
• AGEP is generally attributed to the patient treatment with particular drugs and seems to be related to an altered T cells activity.
• Terbinafine treatment might also induce dermatomyositis, a severe autoimmune connective tissue disease characterized by erythema, muscle weakness and interstitial pulmonary fibrosis (Magro C. M. et al, J. Cutan. Pathol., 2008; 35, 74-81).
• Terbinafine might cause severe liver injuries (Perveze Z. et al, Liver Transpl., 2007; 13, 162-164).
• Griseofulvin is a benzofurane introduced in 1960 for the treatment of dermatophyte infections. The compound induces its fungistatic activity by interfering with microtubule production. Griseofulvin displays limited activity in the treatment of onychomycoses and frequently causes severe side effects such as nausea, diarrhea, headache, confusion and fatigue (Korting H. C. et al, Antimicrob. Agents Chemother., 1993; 37, 2064-2068) that can cause the treatment discontinuation.
• the two /V-Hydroxy pyridones Ciclopirox olamine and Octopirox, seem to mainly act by chelating polyvalent cations, resulting in the inhibition of the metal-dependent enzymes. They are employed against different fungai infections but their use is limited to topical treatment.
• the echinocandins ⁇ Caspofungin, icafungin, Anidulafungin) are semisynthetic lipo-peptides and are the most recently introduced antimycotic drugs. They act by non-competitively inhibiting p-(1-3)-Dglucan synthase, an enzyme essential for the maintenance of the cell wall and are mainly used for intravenous treatment of invasive candidiasis and aspergillosis. They are fungicidal against yeast but only fungistatic against filamentous fungi; in addition, they are quite inactive against dimorphic fungi such as Blastomyces and Histoplasma. Echinocandins are generally well tolerated but animal reproduction studies showed adverse effects on fetus. For this reason FDA lists echinocandins as a pregnancy-risk category C (http://www.fda.gov/medwatch/SAFETY/2004/mar_PI/Cancidas_PI.pdf;
• EP1375486 discloses a generic and very broad class of compounds having HIV integrase inhibitory activity.
• This broad generic class includes 8-hydroxy- quinoline derivatives substituted by a wide variety of substituents, e.g., substituted carboxamide groups at the 7-position. None of the specific compounds disclosed in this reference are structurally similar to the compounds of the present invention.
• EP1541558 discloses a generic and very broad class of compounds having HIV integrase inhibitory activity.
• the specific compounds disclosed in this reference always bear a substituent on the pyridyl ring and preferably are 3-(4-fluorobenzyi)-8-hydroxyquino!ines. None of the specific compounds disclosed in this reference are structurally similar to the compounds of the present invention.
• WO98/11073 discloses a generic class of anti-viral compounds having HIV integrase inhibitory activity. None of the specific compounds disclosed in this reference are structurally similar to the compounds of the present invention.
• WO02/30426 discloses a generic class of compounds having HIV integrase inhibitory activity. As a matter of fact, most of the specific compounds disclosed in this reference bear a naphthydrinyl residue. None of the specific compounds disclosed in this reference are structurally similar to the compounds of the present invention.
• WO02/30930 discloses a generic and very broad class of compounds having HIV integrase inhibitory activity. None of the specific compounds disclosed in this reference are structurally similar to the compounds of the present invention.
• US0326330 and US0326328 disclose fungicidal compositions comprising a combination of two fungicides, one of which is a quinoiine or cinnoline compound. None of the specific compounds disclosed in this reference are structurally similar to the compounds of the present invention.
• WO96/320 5 discloses synergistic fungicidal compositions made of quinoiine derivatives and cytochrome complex 111 inhibitors. None of the specific compounds disclosed in this reference are structurally similar to the compounds of the present invention. US6194413 discloses picolinoyl derivatives which are reported to be useful for treating viral, fungal or bacterial infections.
• EP1669348 discloses antifungal agents defined by a very broad formula which includes certain secondary amides.
• the present invention particularly provides compounds of general formula (I), endowed with a potent antifungal activity
• Ri is:
• F3 ⁇ 4 and R3, independently from each other, are selected from:
• R4 and R 5 are selected from:
• R 6 is:
• n is an integer from 0 to 6;
• C1 -C6 alkyl means linear or branched chain alkyl groups having from 1 to 6 carbon atoms and includes all of the hexy! and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyi, ethyl and methyl.
• cycloalkyl means a cyclic ring of an alkane selected from cyclopropyl, cyclobutyl, cyclopentyi, cyclohexyl, cycloheptyl and cyciooctyl.
• aryl refers to aromatic mono- and poly-carbocyclic ring systems, wherein the individual carbocyclic rings in the polyring systems may be fused or attached to each other via a single bond. Suitable aryl groups include, but are not limited to, phenyl, naphthyl and biphenyl.
• heterocycle broadly refers to a 4- to 8-membered monocyclic rings, 7- to 12-membered bicyclic ring systems or an 11- to 16-membered tricyclic ring system, any ring of which is saturated or unsaturated, and which consists of carbon atoms and one or more heteroatoms selected from N, 0 and S, and wherein the nitrogen and sulphur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
• the hetorocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure.
• the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
• heteromonocycfe refers to a 4- to 8-membered monocyclic ring which is saturated or unsaturated, and which consists of carbon atoms and one or more heteroatoms selected from N, 0 and S, and wherein the nitrogen and sulphur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
• the heterocycle ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure. When the heterocycle ring is an aromatic heterocycle ring it can be defined "heteroaromatic ring".
• an “unsaturated” ring is a partially or fully unsaturated ring.
• an “unsaturated monocyclic C 6 carbocycle” refers to cyclohexene, cyclohexadiene and benzene.
• substituted includes mono- and poly-substitution by a named substituent to the extent such single and multiple substitution is chemically allowed.
• a carbocycle or heterocycle substituted with more than one substituent can have multiple substituents on the same ring atom to the extent it is chemically permitted.
• “Pharmaceutically acceptable salts or derivatives” refers to those salts or derivatives which possess the biological effectiveness and properties of the parent compound and which are not biologically or otherwise undesirable. Such salts include those with inorganic or organic acids, as for instance, the hydrobromide, hydrochloride, sulfate, phosphate, sodium salt, magnesium salt; such derivatives include the esters, the ethers and the N-oxides.
• the compounds of the present invention and their pharmaceutical acceptable salts or derivatives may have asymmetric centres and may occur, except when specifically noted, as mixtures of stereoisomers or as individual diastereomers, or enantiomers, with all isomeric forms being included in the present invention.
• pharmaceutically acceptable refers to molecular entities and other ingredients of such formulations that are physiologically tolerable and do not typically produce untoward reactions when administered to an animal such as a mamma! (e.g. , a human).
• pharmaceutically acceptable means approved by a regulatory agency, such as the FDA or the EMEA, or listed in the U.S. or European Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.
• Ri is:
• F3 ⁇ 42 and R3, independently from each other, are selected from:
• n is an integer from 0 to 6, preferably from 0 to 2. Further preferably in formula (I):
• R 2 and R 3 are different from H and are, independently:
• n is an integer from 0 to 6, preferably from 0 to 2.
• R 2 is different from R 3 .
• Preferred compounds of the invention include, but are not limited to, compounds selected from the group consisting of:
• the compounds of the present invention are selected from: (8-Hydroxyquinolin-7-yl)(isoindo!in-2-yl)methanone (Example 10);
• the compounds of the present invention can be prepared by the coupling of suitable 8-hydroxyquinoiin-7-carboxylic acids 1-1 (or acid derivatives such as acid haiides or esters) with the appropriate amines 1-2, as represented by the following general Chart 1 :
• the hydroxyl group of the carboxyiic acid can be protected (as described in Bioorg. Med. Chem., ⁇ , 2006, 5742-5755 or Synthesis, 12, 1997, 1425-1428 or DE540842) before performing the coupling with the amine and deprotected in the final stage.
• Charts 2-3 below illustrate and expand upon the chemistry portrayed in Chart
• carboxyiic acid 2-1 (which is prepared in Preparation 4 below) was obtained by reaction of commercially available 8-hydroxyquinoline-7- carboxylic acid with one equivalent of bromine in acetic acid (International Publication W098/1 1073, published 19 March 1998).
• carboxyiic acids 2-1 can be prepared from the corresponding commercially available starting materials 5-halo-8- hydroxyquinolines using the methods described in international Publication WO98/11073, published 9 March 1998.
• carboxyiic acid 2-1 was prepared by reaction of the corresponding ethyl ester with a mixture of HN0 3 and H 2 S0 4 followed by alkaline hydrolysis.
• Method A-C UPLC with Sample Manager and 2996 PDA Detector (Waters) interfaced with a Mass Spectrometer Single Quadrupole ZQ (Waters).
• ZQ interface ESI positive mode.
• Method C 0-0.50 min (A: 95%, B: 5%»), 6.00 min (A: 0%, B: 100%o), 6.00-7.00 (A: 0%, B: 100%.), 7.10 min (A: 95%, B: 5%,), 7.10-8.50 min (A: 95%, B: 5%).
• Method D Waters 1525 HPLC pump (Waters) and 2996 PDA detector (Waters) interfaced with a Mass Spectrometer Single Quadrupole ZQ (Waters). ZQ interface: ESI positive mode. Full scan from 102 to 900 amu.
• Method E UPLC with Sample Manager and 2996 PDA Detector (Waters) interfaced with a Mass Spectrometer Single Quadrupole ZQ (Waters).
• ZQ interface ESI positive mode. Full scan from 100 to 600 amu. Capillary 3.25V, cone 26V, extractor 3V, source temperature 20°C, desolvation temperature 400°C, gas fiow 800L/h, cone 100L/h. Column Aquity UPLC-BEH C18 (50x2.1 mm, 1.7 pm). Flow rate 0.5 mL/min, column at 40°C, injection 2 pL.
• a phase water/CH 3 CN 95/5 + 0.1 % TFA
• B phase water/CH 3 CN - 5/95 + 0.1 % TFA. 0 min (A: 95%, B: 5%), 0.30 min (A: 92%, B: 8%), 1.50 min (A: 0%, B: 100%), 1.50-2.00 min (A: 0%, B: 100%).
• Method F Waters 1525 HPLC pump (Waters) and 2996 PDA detector (Waters) interfaced with a Mass Spectrometer Single Quadrupole ZQ (Waters).
• ZQ interface ESI positive mode. Full scan from 102 to 900 amu. Capillary 3.2V, cone 25V, extractor 3V, RF 0.3V, source temperature 1 15°C, desolvation temperature 350°C, gas fiow 600 L h, cone 100 L h. Column Synergy C18 (20x2.0 mm, 2.5 pm). Flow rate 0.7 mL/min, injection 2 pL.
• the column used is a Waters Symmetry Prep C18 column whose dimensions are 19 mm internal diameter by 300 mm in length.
• the stationary phase particle size is 7 pm.
• Aqueous solvent water/CH 3 CN 90/10 + 0.05% TFA.
• Needle rinse solvent /-PrOH.
• Step B A - ethyl-1 -(4-(2-phenylpropan-2-yl)phenyl)methanamine hydrochloride
• the reaction mixture was then quenched with H 2 0 and an aqueous saturated solution of sodium hydrogen carbonate, and twice extracted with DCM.
• the separated organics were dried over Na 2 S0 4 , filtered and concentrated under reduced pressure.
• the residue was purified by preparative HPLC. Product- containing fractions were combined, made basic with a saturated aqueous solution of sodium hydrogen carbonate and CH 3 CN was removed under reduced pressure.
• the aqueous phase was extracted with DCM and the separated organics dried over Na 2 S0 4 , filtered and concentrated to dryness, affording the title compound (19 mg, 0.06 mmol) as a off-white solid.
• Organisms used to test antifungal activity are used to test antifungal activity
• Trichophyton Rubrum (ATCC 28188, PBI International), Trichophyton Mentagrophytes (ATCC 9533, PBI International), Aspergillus Niger (ATCC 16404, PBI International), Scopulariopsis Brevicaulis (ATCC 36840, DSMZ), Candida Albicans (ATCC 90028, PBI International), Candida Glabrata (ATCC 90030, DSMZ).
• Strains were prepared from freeze-dried ampoules or freeze-dried pellets.
• MIC minimal inhibition concentration
• Assays were carried out in RPMI 1640 with L-glutamine medium buffered to pH 7 with 0.165M 3-(N-morpholino)propanesulfonic acid (MOPS) and 10 NaOH and supplemented with 18 g glucose/litre. The tests were performed using 96 well sterile plates (inoculum size of 1 x 10 5 CFU/mL). Compounds stock solutions were prepared at 12.8 mg/mL in 100% DMSO. A series of twofold dilutions were prepared in plate using RPMI 1640. Final concentrations ranged from 0.125 to 128 g/mL at 1 % DMSO.
• MOPS 3-(N-morpholino)propanesulfonic acid
• MIC is defined as the lowest concentration of antifungal agent which prevents any visible growth and was determined after 48h of incubation for yeasts (35°C) and after five days of incubation for filamentous fungi (35°C).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Quinoline Compounds (AREA)

Priority Applications (26)

Applications Claiming Priority (2)

Publications (1)

Family

ID=42026678

Family Applications (1)

Country Status (37)

Cited By (2)

Families Citing this family (6)

Citations (12)

Family Cites Families (8)

• 2009
  • 2009-12-29 EP EP09180902A patent/EP2345643A1/en not_active Withdrawn
• 2010
  • 2010-12-28 SG SG2012042289A patent/SG181586A1/en unknown
  • 2010-12-28 KR KR1020127019421A patent/KR101666505B1/ko not_active Expired - Fee Related
  • 2010-12-28 SI SI201030974T patent/SI2519505T1/sl unknown
  • 2010-12-28 CN CN201510660625.5A patent/CN105384685A/zh active Pending
  • 2010-12-28 ES ES10800763.4T patent/ES2540327T3/es active Active
  • 2010-12-28 HR HRP20150749TT patent/HRP20150749T1/hr unknown
  • 2010-12-28 WO PCT/EP2010/070790 patent/WO2011080264A1/en not_active Ceased
  • 2010-12-28 RS RS20150445A patent/RS54096B1/sr unknown
  • 2010-12-28 PL PL10800763T patent/PL2519505T3/pl unknown
  • 2010-12-28 UA UAA201207789A patent/UA107949C2/ru unknown
  • 2010-12-28 US US13/519,206 patent/US8729098B2/en not_active Expired - Fee Related
  • 2010-12-28 AU AU2010338267A patent/AU2010338267B2/en not_active Ceased
  • 2010-12-28 PT PT108007634T patent/PT2519505E/pt unknown
  • 2010-12-28 NZ NZ600788A patent/NZ600788A/xx not_active IP Right Cessation
  • 2010-12-28 JP JP2012546432A patent/JP5808754B2/ja not_active Expired - Fee Related
  • 2010-12-28 CA CA2783213A patent/CA2783213C/en not_active Expired - Fee Related
  • 2010-12-28 PE PE2012000845A patent/PE20130179A1/es not_active Application Discontinuation
  • 2010-12-28 EP EP10800763.4A patent/EP2519505B1/en active Active
  • 2010-12-28 EA EA201270670A patent/EA025563B1/ru not_active IP Right Cessation
  • 2010-12-28 BR BR112012015728A patent/BR112012015728A2/pt not_active IP Right Cessation
  • 2010-12-28 MX MX2012007748A patent/MX2012007748A/es active IP Right Grant
  • 2010-12-28 DK DK10800763.4T patent/DK2519505T3/en active
  • 2010-12-28 MY MYPI2012002959A patent/MY161869A/en unknown
  • 2010-12-28 GE GEAP201012809A patent/GEP20156244B/en unknown
  • 2010-12-28 PH PH1/2012/501326A patent/PH12012501326A1/en unknown
  • 2010-12-28 CN CN2010800600068A patent/CN102686566A/zh active Pending
  • 2010-12-28 HU HUE10800763A patent/HUE027220T2/hu unknown
• 2012
  • 2012-06-13 ZA ZA2012/04347A patent/ZA201204347B/en unknown
  • 2012-06-14 IL IL220427A patent/IL220427A/en not_active IP Right Cessation
  • 2012-06-15 MA MA34972A patent/MA33829B1/fr unknown
  • 2012-06-22 TN TNP2012000320A patent/TN2012000320A1/en unknown
  • 2012-06-25 GT GT201200216A patent/GT201200216A/es unknown
  • 2012-06-26 CL CL2012001757A patent/CL2012001757A1/es unknown
  • 2012-06-27 DO DO2012000186A patent/DOP2012000186A/es unknown
  • 2012-06-28 EC ECSP12012007 patent/ECSP12012007A/es unknown
  • 2012-06-28 NI NI201200114A patent/NI201200114A/es unknown
• 2015
  • 2015-07-13 CY CY20151100609T patent/CY1116493T1/el unknown
  • 2015-07-30 SM SM201500182T patent/SMT201500182B/xx unknown

Patent Citations (13)

Non-Patent Citations (22)

Also Published As

Similar Documents

Legal Events